EA019793B1 - 5-фенилизоксазол-3-карбоксамиды с противоопухолевыми активностями, модулирующие hsp90 - Google Patents
5-фенилизоксазол-3-карбоксамиды с противоопухолевыми активностями, модулирующие hsp90 Download PDFInfo
- Publication number
- EA019793B1 EA019793B1 EA201170139A EA201170139A EA019793B1 EA 019793 B1 EA019793 B1 EA 019793B1 EA 201170139 A EA201170139 A EA 201170139A EA 201170139 A EA201170139 A EA 201170139A EA 019793 B1 EA019793 B1 EA 019793B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- isoxazole
- carboxylic acid
- dihydroxyphenyl
- chloro
- isopropylphenyl
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 4
- ASVXNFGUPSDDTA-UHFFFAOYSA-N 5-phenyl-1,2-oxazole-3-carboxamide Chemical class O1N=C(C(=O)N)C=C1C1=CC=CC=C1 ASVXNFGUPSDDTA-UHFFFAOYSA-N 0.000 title 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 title 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 title 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 239000003814 drug Substances 0.000 claims abstract description 23
- 201000011510 cancer Diseases 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- -1 atoms halogen Chemical class 0.000 claims description 123
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims description 7
- 201000006474 Brain Ischemia Diseases 0.000 claims description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- NRDHRUUAIBGJLZ-UHFFFAOYSA-N chembl1940919 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(=O)C(C)(C)C NRDHRUUAIBGJLZ-UHFFFAOYSA-N 0.000 claims description 6
- CLGCYNQGBOFRIU-UHFFFAOYSA-N chembl1940924 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(=O)CCN1CCOCC1 CLGCYNQGBOFRIU-UHFFFAOYSA-N 0.000 claims description 6
- NBPOVHXUKYASOM-UHFFFAOYSA-N chembl1940926 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C(C)(C)C NBPOVHXUKYASOM-UHFFFAOYSA-N 0.000 claims description 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 6
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- FPGYLUIGKHTKQV-UHFFFAOYSA-N chembl1940917 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(=O)C=1SC=CC=1C FPGYLUIGKHTKQV-UHFFFAOYSA-N 0.000 claims description 5
- QCKQEYDGLASTLI-UHFFFAOYSA-N chembl1940923 Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=C(C=2C(=CC(O)=C(Cl)C=2)O)ON=C1C(=O)N1CC(F)(F)C1 QCKQEYDGLASTLI-UHFFFAOYSA-N 0.000 claims description 5
- NNPUKYHSBUTURK-IYARVYRRSA-N chembl1940928 Chemical compound C1C[C@@H](CCCCC)CC[C@@H]1C(=O)NC1=C(C=2C(=CC(O)=C(C(C)C)C=2)O)ON=C1C(=O)NCC NNPUKYHSBUTURK-IYARVYRRSA-N 0.000 claims description 5
- WURSGCMBSCSYOG-UHFFFAOYSA-N chembl1941050 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)CCN1CCOCC1 WURSGCMBSCSYOG-UHFFFAOYSA-N 0.000 claims description 5
- BYAGRVGRUDLLDR-UHFFFAOYSA-N chembl1941052 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C1=CC=C(OC)C=C1 BYAGRVGRUDLLDR-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- KJLFFCRGGGXQKE-UHFFFAOYSA-N 1h-indole-6-carboxamide Chemical compound NC(=O)C1=CC=C2C=CNC2=C1 KJLFFCRGGGXQKE-UHFFFAOYSA-N 0.000 claims description 4
- MUZNLZVOKJVBPC-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[(4-methoxycyclohexanecarbonyl)amino]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C1CCC(OC)CC1 MUZNLZVOKJVBPC-UHFFFAOYSA-N 0.000 claims description 4
- IYYXMUJIVUJPBD-UHFFFAOYSA-N N-[5-(5-chloro-2,4-dihydroxyphenyl)-3-(4-methylpiperazine-1-carbonyl)-1,2-oxazol-4-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=C(C=2C(=CC(O)=C(Cl)C=2)O)ON=C1C(=O)N1CCN(C)CC1 IYYXMUJIVUJPBD-UHFFFAOYSA-N 0.000 claims description 4
- WASBTDRFRYYYRL-UHFFFAOYSA-N chembl1940916 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(=O)C1=CC(OC)=C(OC)C(OC)=C1 WASBTDRFRYYYRL-UHFFFAOYSA-N 0.000 claims description 4
- WEAJPAPZLYQPRZ-UHFFFAOYSA-N chembl1940918 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(C)=O WEAJPAPZLYQPRZ-UHFFFAOYSA-N 0.000 claims description 4
- VIEGTSLOUDDFCN-UHFFFAOYSA-N chembl1940920 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(=O)C=C VIEGTSLOUDDFCN-UHFFFAOYSA-N 0.000 claims description 4
- KBNLPGKGXMPKID-UHFFFAOYSA-N chembl1940925 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(C)=O KBNLPGKGXMPKID-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- LHNUEBNTPQPHKG-UHFFFAOYSA-N methyl 5-[[[5-(5-chloro-2,4-dihydroxyphenyl)-3-(ethylcarbamoyl)-1,2-oxazol-4-yl]amino]methyl]-1,2-oxazole-3-carboxylate Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NCC1=CC(C(=O)OC)=NO1 LHNUEBNTPQPHKG-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000009182 Parasitemia Diseases 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- UWKWOTCLGZNOKY-UHFFFAOYSA-N chembl1940913 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(=O)C1=CC=C(Br)C=C1 UWKWOTCLGZNOKY-UHFFFAOYSA-N 0.000 claims description 3
- QBSZQEVMVGSPFZ-UHFFFAOYSA-N chembl1940914 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(=O)C1=CC=C(OC)C=C1 QBSZQEVMVGSPFZ-UHFFFAOYSA-N 0.000 claims description 3
- MQYOAYAUVZORFG-UHFFFAOYSA-N chembl1940915 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC(=O)C1=CC=C(OC)C(OC)=C1 MQYOAYAUVZORFG-UHFFFAOYSA-N 0.000 claims description 3
- FREXQSXQFGJSPD-UHFFFAOYSA-N chembl1940927 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C1CCCCC1 FREXQSXQFGJSPD-UHFFFAOYSA-N 0.000 claims description 3
- ZSKNESXDGZRCNG-UHFFFAOYSA-N chembl1940929 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C1CCC(C(F)(F)F)CC1 ZSKNESXDGZRCNG-UHFFFAOYSA-N 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 230000036642 wellbeing Effects 0.000 claims description 3
- XNNRAUOEJJPCTG-UHFFFAOYSA-N 3-ethyl-2H-1,2-oxazole-3,5-dicarboxamide Chemical compound C(C)C1(NOC(=C1)C(=O)N)C(=O)N XNNRAUOEJJPCTG-UHFFFAOYSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102100032187 Androgen receptor Human genes 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- ZHOPMAPGOGTAOR-UHFFFAOYSA-N chembl1940931 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C1CCC(C(C)(C)C)CC1 ZHOPMAPGOGTAOR-UHFFFAOYSA-N 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000004224 pleura Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 5
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract description 3
- 108010006519 Molecular Chaperones Proteins 0.000 abstract description 3
- 102000005431 Molecular Chaperones Human genes 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 2
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 abstract 2
- 238000005481 NMR spectroscopy Methods 0.000 description 109
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 105
- 239000000203 mixture Substances 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 102100037580 Sesquipedalian-1 Human genes 0.000 description 12
- 101710169844 Sesquipedalian-1 Proteins 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- UXYRXGFUANQKTA-UHFFFAOYSA-N 1,2-oxazole-3-carboxylic acid Chemical compound OC(=O)C=1C=CON=1 UXYRXGFUANQKTA-UHFFFAOYSA-N 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- BWFGXQOWFKYXOZ-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-nitro-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1[N+]([O-])=O BWFGXQOWFKYXOZ-UHFFFAOYSA-N 0.000 description 5
- 101150072179 ATP1 gene Proteins 0.000 description 5
- 101100003366 Arabidopsis thaliana ATPA gene Proteins 0.000 description 5
- 102100021649 Elongator complex protein 6 Human genes 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 101100065219 Homo sapiens ELP6 gene Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 101150105046 atpI gene Proteins 0.000 description 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- SURLAOAQRDUOFO-UHFFFAOYSA-N chembl1941081 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NCC1=CC=C(OC)C=C1 SURLAOAQRDUOFO-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- QACSKDRRGBHPOF-UHFFFAOYSA-N ethyl 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxylate Chemical compound O1N=C(C(=O)OCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(Cl)=C1OCC1=CC=CC=C1 QACSKDRRGBHPOF-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- CVJQCEUAIVQCDK-UHFFFAOYSA-N 1-(5-chloro-2,4-dihydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(Cl)=C(O)C=C1O CVJQCEUAIVQCDK-UHFFFAOYSA-N 0.000 description 3
- KEUCDMZJTGJAQX-UHFFFAOYSA-N 1-[5-chloro-2,4-bis(phenylmethoxy)phenyl]ethanone Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C)=CC(Cl)=C1OCC1=CC=CC=C1 KEUCDMZJTGJAQX-UHFFFAOYSA-N 0.000 description 3
- JKTQYVXIHSTRDD-UHFFFAOYSA-N 4-amino-5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1N JKTQYVXIHSTRDD-UHFFFAOYSA-N 0.000 description 3
- IRUQDZYRLKBZPY-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-3-carboxylic acid Chemical compound O1N=C(C(=O)O)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(Cl)=C1OCC1=CC=CC=C1 IRUQDZYRLKBZPY-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010063094 Cerebral malaria Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- JZWQGHAERZIZGM-UHFFFAOYSA-N n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C=1C=CON=1 JZWQGHAERZIZGM-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- MQMMXOIRKBDWGP-UHFFFAOYSA-N 4-ethyl-1,2-oxazole-3,5-dicarboxamide Chemical compound C(C)C=1C(=NOC1C(=O)N)C(=O)N MQMMXOIRKBDWGP-UHFFFAOYSA-N 0.000 description 2
- NQPSABXSIXZZFR-UHFFFAOYSA-N 4-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCC1=CON=C1C(N)=O NQPSABXSIXZZFR-UHFFFAOYSA-N 0.000 description 2
- SLBKTQWZSYURPV-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[[3-(hydroxymethyl)-1,2-oxazol-5-yl]methylamino]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NCC1=CC(CO)=NO1 SLBKTQWZSYURPV-UHFFFAOYSA-N 0.000 description 2
- MYEXHIZUUXNARE-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)NCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(Cl)=C1OCC1=CC=CC=C1 MYEXHIZUUXNARE-UHFFFAOYSA-N 0.000 description 2
- DCTZTCHQDXIRFO-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-(prop-2-enoylamino)-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1NC(=O)C=C DCTZTCHQDXIRFO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000587820 Homo sapiens Selenide, water dikinase 1 Proteins 0.000 description 2
- 101000701815 Homo sapiens Spermidine synthase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100031163 Selenide, water dikinase 1 Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- UOWFKIGORLIVGO-UHFFFAOYSA-N chembl1941063 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C=1SC=CC=1C UOWFKIGORLIVGO-UHFFFAOYSA-N 0.000 description 2
- FPBCOFYFVBCSPA-UHFFFAOYSA-N chembl1941083 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC1CCN(C)CC1 FPBCOFYFVBCSPA-UHFFFAOYSA-N 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 2
- 229930192524 radicicol Natural products 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- FTJHKZQHQDKPFJ-UHFFFAOYSA-N (carbamoylamino)carbamic acid Chemical group NC(=O)NNC(O)=O FTJHKZQHQDKPFJ-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- QUHVRXKSQHIZNV-UHFFFAOYSA-N 3,3-difluoroazetidine Chemical compound FC1(F)CNC1 QUHVRXKSQHIZNV-UHFFFAOYSA-N 0.000 description 1
- INVJBYOXKDTRAB-UHFFFAOYSA-N 3,3-difluoroazetidine-1-carbaldehyde Chemical compound FC1(F)CN(C=O)C1 INVJBYOXKDTRAB-UHFFFAOYSA-N 0.000 description 1
- JRQYHEBAMCAWLG-UHFFFAOYSA-N 3-(2,2,2-trifluoroethyl)-1,2-oxazole Chemical compound FC(CC1=NOC=C1)(F)F JRQYHEBAMCAWLG-UHFFFAOYSA-N 0.000 description 1
- QENGPZGAWFQWCZ-UHFFFAOYSA-N 3-Methylthiophene Chemical compound CC=1C=CSC=1 QENGPZGAWFQWCZ-UHFFFAOYSA-N 0.000 description 1
- XPQPCDFVNITMSY-UHFFFAOYSA-N 3-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazole-5-carboxylic acid Chemical compound O1C(C(=O)O)=CC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=N1 XPQPCDFVNITMSY-UHFFFAOYSA-N 0.000 description 1
- YCEITAYVODNFFB-UHFFFAOYSA-N 4-[(4-bromobenzoyl)amino]-5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C1=CC=C(Br)C=C1 YCEITAYVODNFFB-UHFFFAOYSA-N 0.000 description 1
- LGAIEBFEXMBFIL-UHFFFAOYSA-N 4-[(4-bromobenzoyl)amino]-5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1NC(=O)C1=CC=C(Br)C=C1 LGAIEBFEXMBFIL-UHFFFAOYSA-N 0.000 description 1
- CADKYMFSDFMGIJ-UHFFFAOYSA-N 4-acetamido-5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)=C1NC(C)=O CADKYMFSDFMGIJ-UHFFFAOYSA-N 0.000 description 1
- WHUNSZBDQCBJQO-UHFFFAOYSA-N 4-acetamido-5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1NC(C)=O WHUNSZBDQCBJQO-UHFFFAOYSA-N 0.000 description 1
- JFZARAAVWNISTG-UHFFFAOYSA-N 4-amino-5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1N JFZARAAVWNISTG-UHFFFAOYSA-N 0.000 description 1
- ADQACDHOUOIMAK-UHFFFAOYSA-N 4-amino-5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)=C1N ADQACDHOUOIMAK-UHFFFAOYSA-N 0.000 description 1
- WAKROMYHSIMZFY-UHFFFAOYSA-N 4-amino-5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1N WAKROMYHSIMZFY-UHFFFAOYSA-N 0.000 description 1
- JQVAPEJNIZULEK-UHFFFAOYSA-N 4-chlorobenzene-1,3-diol Chemical compound OC1=CC=C(Cl)C(O)=C1 JQVAPEJNIZULEK-UHFFFAOYSA-N 0.000 description 1
- VCJCQTZWCRSVKF-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[(3,4-dimethoxybenzoyl)amino]-N-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C1=CC=C(OC)C(OC)=C1 VCJCQTZWCRSVKF-UHFFFAOYSA-N 0.000 description 1
- ANIDUTPIZUBSKJ-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-(prop-2-enoylamino)-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NC(=O)C=C ANIDUTPIZUBSKJ-UHFFFAOYSA-N 0.000 description 1
- DILNMOLOZGRZPP-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[(4-methoxyphenyl)sulfonylamino]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1NS(=O)(=O)C1=CC=C(OC)C=C1 DILNMOLOZGRZPP-UHFFFAOYSA-N 0.000 description 1
- UBXHYPNJROELMK-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-4-[(3,4-dimethoxybenzoyl)amino]-1,2-oxazole-3-carboxylic acid Chemical compound ClC=1C(=CC(=C(C=1)C1=C(C(=NO1)C(=O)O)NC(C1=CC(=C(C=C1)OC)OC)=O)O)O UBXHYPNJROELMK-UHFFFAOYSA-N 0.000 description 1
- SJDOHMRKSZXBMK-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-nitro-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1[N+]([O-])=O SJDOHMRKSZXBMK-UHFFFAOYSA-N 0.000 description 1
- QAVOEBGLMLVWAK-UHFFFAOYSA-N 5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-4-(2,2-dimethylpropanoylamino)-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)=C1NC(=O)C(C)(C)C QAVOEBGLMLVWAK-UHFFFAOYSA-N 0.000 description 1
- BEZNKTGLEYAPEN-UHFFFAOYSA-N 5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)NCC)C=C1C(C(=C1)OCC=2C=CC=CC=2)=CC(C(C)C)=C1OCC1=CC=CC=C1 BEZNKTGLEYAPEN-UHFFFAOYSA-N 0.000 description 1
- BRMJTMKDPSHGOW-UHFFFAOYSA-N 5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-n-ethyl-4-(3-morpholin-4-ylpropanoylamino)-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)=C1NC(=O)CCN1CCOCC1 BRMJTMKDPSHGOW-UHFFFAOYSA-N 0.000 description 1
- QIPAQNDIMGAAMJ-UHFFFAOYSA-N 5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-n-ethyl-4-nitro-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(C(C)C)C=2)OCC=2C=CC=CC=2)=C1[N+]([O-])=O QIPAQNDIMGAAMJ-UHFFFAOYSA-N 0.000 description 1
- ILIVQNJCOJCRPH-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-(2,2-dimethylpropanoylamino)-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1NC(=O)C(C)(C)C ILIVQNJCOJCRPH-UHFFFAOYSA-N 0.000 description 1
- DLJUZIDKULMLDN-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-[(3,4-dimethoxybenzoyl)amino]-n-ethyl-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1NC(=O)C1=CC=C(OC)C(OC)=C1 DLJUZIDKULMLDN-UHFFFAOYSA-N 0.000 description 1
- IXDWJXUTMOGDMZ-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-(3-morpholin-4-ylpropanoylamino)-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1NC(=O)CCN1CCOCC1 IXDWJXUTMOGDMZ-UHFFFAOYSA-N 0.000 description 1
- JQVYTFRFFPWMAX-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-[(3,4,5-trimethoxybenzoyl)amino]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1NC(=O)C1=CC(OC)=C(OC)C(OC)=C1 JQVYTFRFFPWMAX-UHFFFAOYSA-N 0.000 description 1
- CWNYOLYQPXNKBP-UHFFFAOYSA-N 5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-n-ethyl-4-[(4-methoxybenzoyl)amino]-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1NC(=O)C1=CC=C(OC)C=C1 CWNYOLYQPXNKBP-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DUYLDQSQDSOXOT-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C=C(C(=C1)OCC1=CC=CC=C1)Cl)C(C=C(C(=O)O)O)=O Chemical compound C(C1=CC=CC=C1)OC1=C(C=C(C(=C1)OCC1=CC=CC=C1)Cl)C(C=C(C(=O)O)O)=O DUYLDQSQDSOXOT-UHFFFAOYSA-N 0.000 description 1
- UOCGHKPNBDOLDX-UHFFFAOYSA-N C1=C(OCC=2C=CC=CC=2)C(C(=O)C=C(O)C(=O)OCC)=CC(Cl)=C1OCC1=CC=CC=C1 Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)C=C(O)C(=O)OCC)=CC(Cl)=C1OCC1=CC=CC=C1 UOCGHKPNBDOLDX-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 101000866018 Homo sapiens DnaJ homolog subfamily B member 1 Proteins 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical class CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FQHUAZWCZVSVPV-UHFFFAOYSA-N [4-amino-5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazol-3-yl]-(3,3-difluoroazetidin-1-yl)methanone Chemical compound NC=1C(C(=O)N2CC(F)(F)C2)=NOC=1C(C(=C1)OCC=2C=CC=CC=2)=CC(Cl)=C1OCC1=CC=CC=C1 FQHUAZWCZVSVPV-UHFFFAOYSA-N 0.000 description 1
- ZCJVOILPGQRKJT-UHFFFAOYSA-N [5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-1,2-oxazol-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1 ZCJVOILPGQRKJT-UHFFFAOYSA-N 0.000 description 1
- QZONGGRECUYAST-UHFFFAOYSA-N [5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-nitro-1,2-oxazol-3-yl]-(3,3-difluoroazetidin-1-yl)methanone Chemical compound [O-][N+](=O)C=1C(C(=O)N2CC(F)(F)C2)=NOC=1C(C(=C1)OCC=2C=CC=CC=2)=CC(Cl)=C1OCC1=CC=CC=C1 QZONGGRECUYAST-UHFFFAOYSA-N 0.000 description 1
- HISNKJRPJWKDBS-UHFFFAOYSA-N [5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-4-nitro-1,2-oxazol-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=NOC(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)=C1[N+]([O-])=O HISNKJRPJWKDBS-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Substances FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- UDIGLEOGQYIBNW-UHFFFAOYSA-N chembl1941080 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NCC=1SC=CC=1C UDIGLEOGQYIBNW-UHFFFAOYSA-N 0.000 description 1
- OOHHYUCVSBGXHT-UHFFFAOYSA-N chembl1941082 Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(Cl)C=2)O)=C1NC1CCCCC1 OOHHYUCVSBGXHT-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- ZTUJDPKOHPKRMO-UHFFFAOYSA-N hydron;2,2,2-trifluoroethanamine;chloride Chemical compound Cl.NCC(F)(F)F ZTUJDPKOHPKRMO-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- VYKALIRICXHOJI-UHFFFAOYSA-N n-[5-[5-chloro-2,4-bis(phenylmethoxy)phenyl]-3-(3,3-difluoroazetidine-1-carbonyl)-1,2-oxazol-4-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=C(C=2C(=CC(OCC=3C=CC=CC=3)=C(Cl)C=2)OCC=2C=CC=CC=2)ON=C1C(=O)N1CC(F)(F)C1 VYKALIRICXHOJI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinyl group Chemical group C1(O)=CC(O)=CC=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- QXPZOKVSFMRGMQ-UHFFFAOYSA-N trifluoromethylcyclohexane Chemical compound FC(F)(F)C1CCCCC1 QXPZOKVSFMRGMQ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08159692 | 2008-07-04 | ||
| PCT/EP2009/058205 WO2010000748A1 (en) | 2008-07-04 | 2009-06-30 | 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201170139A1 EA201170139A1 (ru) | 2011-08-30 |
| EA019793B1 true EA019793B1 (ru) | 2014-06-30 |
Family
ID=40019071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170139A EA019793B1 (ru) | 2008-07-04 | 2009-06-30 | 5-фенилизоксазол-3-карбоксамиды с противоопухолевыми активностями, модулирующие hsp90 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8383616B2 (enExample) |
| EP (1) | EP2310377B1 (enExample) |
| JP (1) | JP5640002B2 (enExample) |
| KR (1) | KR20110050615A (enExample) |
| CN (1) | CN102083804A (enExample) |
| AR (1) | AR072793A1 (enExample) |
| AU (1) | AU2009265745B2 (enExample) |
| BR (1) | BRPI0913834A2 (enExample) |
| CA (1) | CA2729710A1 (enExample) |
| EA (1) | EA019793B1 (enExample) |
| IL (1) | IL210200A0 (enExample) |
| MX (1) | MX2010013913A (enExample) |
| MY (1) | MY150604A (enExample) |
| NZ (1) | NZ590861A (enExample) |
| SG (1) | SG192464A1 (enExample) |
| TW (1) | TWI450898B (enExample) |
| WO (1) | WO2010000748A1 (enExample) |
| ZA (1) | ZA201100007B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236838B2 (en) * | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| KR101945383B1 (ko) | 2010-10-27 | 2019-02-07 | 픽셀리전트 테크놀로지스 엘엘씨 | 나노결정의 합성, 캐핑 및 분산 |
| KR101275264B1 (ko) | 2011-08-24 | 2013-06-17 | 포항공과대학교 산학협력단 | 샤프로닌 단백질의 조절 물질 탐색 방법 |
| CN103724269B (zh) * | 2012-10-11 | 2016-12-21 | 中国科学院上海药物研究所 | 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途 |
| MA39483A (fr) * | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp | Agents thérapeutiques cibles |
| US9855249B2 (en) | 2014-10-02 | 2018-01-02 | Flatley Discovery Lab, Llc | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN104725329B (zh) * | 2015-01-13 | 2017-01-18 | 陕西科技大学 | 一种具有抗肿瘤活性的异恶唑羧酸类化合物及其合成方法 |
| HK1246645A1 (zh) | 2015-03-27 | 2018-09-14 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CN104803934B (zh) * | 2015-05-04 | 2018-01-02 | 陕西科技大学 | 一种具有抗肿瘤活性的苯基异噁唑羧酸类化合物及其合成方法与应用 |
| IT201700081419A1 (it) * | 2017-07-18 | 2019-01-18 | Rare Partners Srl | Derivati isossazolici come induttori di emoglobina fetale in precursori eritroidi derivati da pazienti beta-talassemici |
| CN112367991A (zh) * | 2018-06-25 | 2021-02-12 | 达纳-法伯癌症研究所股份有限公司 | Taire家族激酶抑制剂及其用途 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN117105880B (zh) * | 2022-10-17 | 2025-08-26 | 上海康斯维克生物医药有限公司 | 用作诱发抗原特异性反应的脲类化合物、其荧光标记物及制备方法和用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004072051A1 (en) * | 2003-02-11 | 2004-08-26 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| WO2007096194A1 (en) * | 2006-02-27 | 2007-08-30 | Novartis Ag | Radio-labeled isoxazole derivatives useful for the labeling and diagnostic of hsp90 functionality |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420878T1 (de) * | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| KR101394245B1 (ko) * | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
| GEP20115309B (en) * | 2007-03-01 | 2011-10-25 | Novartis Ag | Acid addition salts, hydrates and polymorphs of 5-(2,4-dihy-droxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-arboxylic acid ethylamide and formulations comprising these forms |
-
2009
- 2009-06-17 TW TW098120258A patent/TWI450898B/zh not_active IP Right Cessation
- 2009-06-30 WO PCT/EP2009/058205 patent/WO2010000748A1/en not_active Ceased
- 2009-06-30 EA EA201170139A patent/EA019793B1/ru not_active IP Right Cessation
- 2009-06-30 JP JP2011515438A patent/JP5640002B2/ja not_active Expired - Fee Related
- 2009-06-30 KR KR1020117000312A patent/KR20110050615A/ko not_active Ceased
- 2009-06-30 AU AU2009265745A patent/AU2009265745B2/en not_active Ceased
- 2009-06-30 US US13/001,652 patent/US8383616B2/en not_active Expired - Fee Related
- 2009-06-30 SG SG2013051305A patent/SG192464A1/en unknown
- 2009-06-30 CA CA2729710A patent/CA2729710A1/en not_active Abandoned
- 2009-06-30 NZ NZ590861A patent/NZ590861A/xx not_active IP Right Cessation
- 2009-06-30 BR BRPI0913834A patent/BRPI0913834A2/pt not_active IP Right Cessation
- 2009-06-30 MY MYPI20105887 patent/MY150604A/en unknown
- 2009-06-30 EP EP09772448.8A patent/EP2310377B1/en not_active Not-in-force
- 2009-06-30 CN CN2009801255931A patent/CN102083804A/zh active Pending
- 2009-06-30 MX MX2010013913A patent/MX2010013913A/es active IP Right Grant
- 2009-07-03 AR ARP090102496A patent/AR072793A1/es unknown
-
2010
- 2010-12-23 IL IL210200A patent/IL210200A0/en unknown
-
2011
- 2011-01-03 ZA ZA2011/00007A patent/ZA201100007B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004072051A1 (en) * | 2003-02-11 | 2004-08-26 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| WO2007096194A1 (en) * | 2006-02-27 | 2007-08-30 | Novartis Ag | Radio-labeled isoxazole derivatives useful for the labeling and diagnostic of hsp90 functionality |
Non-Patent Citations (1)
| Title |
|---|
| PAUL A. BROUGH ET AL.: "4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, 20 November 2007 (2007-11-20), pages 196-218, XP002506225, cited in the application, the whole document * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010000748A1 (en) | 2010-01-07 |
| MY150604A (en) | 2014-01-30 |
| TW201012815A (en) | 2010-04-01 |
| JP2011526594A (ja) | 2011-10-13 |
| TWI450898B (zh) | 2014-09-01 |
| BRPI0913834A2 (pt) | 2015-10-20 |
| JP5640002B2 (ja) | 2014-12-10 |
| EP2310377A1 (en) | 2011-04-20 |
| KR20110050615A (ko) | 2011-05-16 |
| CA2729710A1 (en) | 2010-01-07 |
| US8383616B2 (en) | 2013-02-26 |
| SG192464A1 (en) | 2013-08-30 |
| CN102083804A (zh) | 2011-06-01 |
| AU2009265745B2 (en) | 2013-07-04 |
| NZ590861A (en) | 2012-08-31 |
| ZA201100007B (en) | 2011-10-26 |
| AU2009265745A1 (en) | 2010-01-07 |
| MX2010013913A (es) | 2011-03-03 |
| AR072793A1 (es) | 2010-09-22 |
| US20110245221A1 (en) | 2011-10-06 |
| EP2310377B1 (en) | 2015-09-16 |
| EA201170139A1 (ru) | 2011-08-30 |
| IL210200A0 (en) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA019793B1 (ru) | 5-фенилизоксазол-3-карбоксамиды с противоопухолевыми активностями, модулирующие hsp90 | |
| CA2409819C (en) | Triazole derivatives | |
| KR100955015B1 (ko) | 2ｈ-프탈라진-1-온 및 이것의 사용 방법 | |
| US10919885B2 (en) | Compounds and uses thereof | |
| TWI268929B (en) | Neurotrophin production/secretion promoting, thiazole and oxazole derivatives | |
| TW572757B (en) | Novel isoxazolinone antibacterial agents | |
| WO2001060819A1 (en) | Novel isoxazole and thiazole compounds and use thereof as drugs | |
| EA026674B1 (ru) | Соединения, применимые в качестве лекарственных средств | |
| WO2021097240A1 (en) | Compounds and uses thereof | |
| US20220079931A1 (en) | Estrogen receptor protein degraders | |
| AU2020424661B2 (en) | Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient | |
| US20040214818A1 (en) | Triazole derivative | |
| CN119365474A (zh) | Stat3抑制剂的前药 | |
| CN119968377A (zh) | 氨基磷酸酯化合物及其用途 | |
| JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
| WO2017034377A1 (en) | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) | |
| WO2019235553A1 (ja) | アゼチジン誘導体及びそのプロドラッグ | |
| IL291418B2 (en) | Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment | |
| TW202444385A (zh) | Ｅｇｆｒ降解劑、其藥物組成物及其用途 | |
| KR20120109667A (ko) | 열쇼크 단백질의 활성을 저해하는 신규 화합물 | |
| HK1158191A (en) | 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |